Last reviewed · How we verify
Rapid-acting insulin secretagogue
At a glance
| Generic name | Rapid-acting insulin secretagogue |
|---|---|
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
- Hypoglycaemia
- Rash
Key clinical trials
- Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)"
- Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes (PHASE3)
- MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes (PHASE3)
- Combination of Glinides With Premixed Insulin (PHASE4)
- Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients (PHASE3)
- Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rapid-acting insulin secretagogue CI brief — competitive landscape report
- Rapid-acting insulin secretagogue updates RSS · CI watch RSS
- Takeda portfolio CI